GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gufic Biosciences Ltd (BOM:509079) » Definitions » Gross Margin %

Gufic Biosciences (BOM:509079) Gross Margin % : 52.92% (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Gufic Biosciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Gufic Biosciences's Gross Profit for the three months ended in Sep. 2024 was ₹1,081 Mil. Gufic Biosciences's Revenue for the three months ended in Sep. 2024 was ₹2,042 Mil. Therefore, Gufic Biosciences's Gross Margin % for the quarter that ended in Sep. 2024 was 52.92%.


The historical rank and industry rank for Gufic Biosciences's Gross Margin % or its related term are showing as below:

BOM:509079' s Gross Margin % Range Over the Past 10 Years
Min: 40.7   Med: 47.87   Max: 51.35
Current: 49.89


During the past 13 years, the highest Gross Margin % of Gufic Biosciences was 51.35%. The lowest was 40.70%. And the median was 47.87%.

BOM:509079's Gross Margin % is ranked better than
55.09% of 962 companies
in the Drug Manufacturers industry
Industry Median: 47.1 vs BOM:509079: 49.89

Gufic Biosciences had a gross margin of 52.92% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Gufic Biosciences was -0.40% per year.


Gufic Biosciences Gross Margin % Historical Data

The historical data trend for Gufic Biosciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gufic Biosciences Gross Margin % Chart

Gufic Biosciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.24 47.61 40.70 49.85 48.12

Gufic Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.22 52.75 37.96 53.29 52.92

Competitive Comparison of Gufic Biosciences's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Gross Margin % falls into.



Gufic Biosciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Gufic Biosciences's Gross Margin for the fiscal year that ended in Mar. 2024 is calculated as

Gross Margin % (A: Mar. 2024 )=Gross Profit (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=3703.6 / 7696.562
=(Revenue - Cost of Goods Sold) / Revenue
=(7696.562 - 3992.924) / 7696.562
=48.12 %

Gufic Biosciences's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=1080.5 / 2041.799
=(Revenue - Cost of Goods Sold) / Revenue
=(2041.799 - 961.29) / 2041.799
=52.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Gufic Biosciences  (BOM:509079) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Gufic Biosciences had a gross margin of 52.92% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Gufic Biosciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Gufic Biosciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gufic Biosciences Business Description

Traded in Other Exchanges
Address
SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.

Gufic Biosciences Headlines

No Headlines